Alixia

Founders

Alixia was founded by Olof Mollstedt and Helen Chen, Ph.D. Olof Mollstedt holds B.S. and M.S. degrees in Engineering Physics from Chalmers University of Technology in Sweden and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. Helen Chen, Ph.D., has over 15 years of experience in the biotech industry. She was previously the Chief Operations Officer at Ambryx Biotechnology. Helen Chen earned her B.S. in molecular biochemistry and biophysics from Yale University and her Ph.D. in biomedical sciences from UCSD, School of Medicine.

History

Alixia, formerly known as Guided Clarity, is based in San Francisco, CA, USA. The company operates within the Healthcare industry, specifically in Therapeutics. It participated in the Y-Combinator W22 batch. Alixia's mission is to develop innovative therapeutic solutions targeting age-related diseases, cancer, and immune dysregulation.

Services

Alixia focuses on developing therapeutic compounds that disrupt metabolic and inflammatory triggers within cancer and quasi-cancerous cells. The company aims to address multiple age-related diseases through an integrated approach that involves biology, biophysics, computational chemistry, and clinical input.

Research and Development

Alixia's therapeutic portfolio includes programs at various stages of preclinical development. These programs target critical areas such as cancer, aging, inflammation, and immune dysregulation. The lead compounds are designed to disrupt the metabolic and inflammatory processes that contribute to disease progression in the microenvironment of targeted cells.

Team Size and Location

Alixia operates with a small but specialized team of 2 members, based in San Francisco, CA, USA. The company's focus spans across the United States and America/Canada regions.

Report inaccurate information

Companies similar to Alixia

Serinus Biosciences, based in New York, NY, is a biotech company focused on developing combination therapies to combat cancer treatment resistance, utilizing an AI platform informed by system biology.

Asher Bio, based in South San Francisco, CA, develops innovative cis-targeted immunotherapies for cancer, autoimmune, and infectious diseases, focusing on precision and reduced side effects.

Arpeggio Bio, based in Boulder, CO, specializes in drug discovery targeting transcription factors with AI and RNA-sequencing technologies. The company, with a team of 20, collaborates with industry giants like J&J and FORMA, focusing on diseases such as IO-resistant melanoma and rare genetic disorders.

Reverie Labs, based in Cambridge, MA, specializes in developing next-generation, brain-penetrant cancer therapies using advanced computational chemistry and machine learning.

Gerostate Alpha, based in Novato, CA, is a healthcare company focused on developing innovative therapeutics to address aging and chronic diseases.

Immunome is a biotechnology company focused on developing innovative cancer therapies, including immunotherapies and targeted treatments, using its proprietary memory B cell hybridoma technology.

HCW Biologics is a clinical-stage company developing transformative immunotherapies to combat cancer and age-related diseases, utilizing its proprietary TOBI™ platform.

Odyssey Therapeutics, recognized on the 2022 Endpoints 11 list, pioneers next-generation precision immunomodulators and oncology medicines, utilizing advanced drug discovery technologies and strategic collaborations.

3T Biosciences develops next-generation therapies for solid tumors and immune-mediated diseases using proprietary technology and machine learning, based in South San Francisco.